[{"address1": "830 Winter Street", "address2": "2nd Floor", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "781 999 0232", "website": "https://www.q32bio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was incorporated in 2017 and is based in Waltham, Massachusetts.", "fullTimeEmployees": 37, "companyOfficers": [{"maxAge": 1, "name": "Ms. Jodie Pope Morrison", "age": 48, "title": "CEO, Secretary & Director", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David S. Grayzel M.D.", "age": 54, "title": "President & Director", "yearBorn": 1969, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shelia M. Violette Ph.D.", "title": "Co-founder, Chief Scientific Officer & President of Research", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lee H. Kalowski M.B.A.", "age": 42, "title": "Chief Financial Officer", "yearBorn": 1981, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Saul  Fink Ph.D.", "title": "Chief Technology Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Appugliese J.D.", "title": "Senior VP & Head of People", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Marzilli M.P.H.", "title": "Executive Vice President of Corporate Strategy & Program Operations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathryn E. Golden M.B.A.", "title": "Head of Chemistry, Manufacturing & Controls", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jason A. Campagna M.D., Ph.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1711929600, "maxAge": 86400, "priceHint": 2, "previousClose": 23.81, "open": 25.6, "dayLow": 25.6, "dayHigh": 30.92, "regularMarketPreviousClose": 23.81, "regularMarketOpen": 25.6, "regularMarketDayLow": 25.6, "regularMarketDayHigh": 30.92, "forwardPE": -4.2266083, "volume": 245689, "regularMarketVolume": 245689, "averageVolume": 26310, "averageVolume10days": 38080, "averageDailyVolume10Day": 38080, "marketCap": 344881856, "fiftyTwoWeekLow": 8.244, "fiftyTwoWeekHigh": 30.92, "priceToSalesTrailing12Months": -51.854137, "fiftyDayAverage": 16.1954, "twoHundredDayAverage": 16.49108, "currency": "USD", "enterpriseValue": 420710048, "floatShares": 4869037, "sharesOutstanding": 11929500, "sharesShort": 10272, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.00090000004, "heldPercentInsiders": 0.0253, "heldPercentInstitutions": 0.65084, "shortRatio": 0.32, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -53743000, "forwardEps": -6.84, "pegRatio": 0.29, "lastSplitFactor": "1:18", "lastSplitDate": 1711411200, "enterpriseToRevenue": -63.255, "enterpriseToEbitda": -8.81, "52WeekChange": 0.28425026, "SandP52WeekChange": 0.2565279, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "QTTB", "underlyingSymbol": "QTTB", "shortName": "Q32 Bio Inc.", "longName": "Q32 Bio Inc.", "firstTradeDateEpochUtc": 1522243800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9b4fb2a4-b0c7-345e-8a95-484dce8eb8d6", "messageBoardId": "finmb_669405676", "gmtOffSetMilliseconds": -14400000, "currentPrice": 28.91, "targetHighPrice": 50.0, "targetLowPrice": 45.0, "targetMeanPrice": 47.5, "targetMedianPrice": 47.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 25617000, "totalCashPerShare": 2.147, "ebitda": -47756000, "totalDebt": 50840000, "quickRatio": 1.869, "currentRatio": 2.035, "totalRevenue": -6651000, "revenuePerShare": -0.917, "returnOnAssets": -0.55424, "freeCashflow": -40899876, "operatingCashflow": -18677000, "operatingMargins": 1.76026, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-12"}]